Drug intelligence / Profile preview

Panflu

Development stage: Phase 4
Lead developer: Omninvest
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Panflu** is Sinovac's monovalent, egg-derived, inactivated whole-virion influenza A H5N1 pandemic-preparedness vaccine adjuvanted with aluminum hydroxide. It uses the NIBRG-14 reassortant vaccine strain, derived from A/Vietnam/1194/2004 and A/PR/8/34, and is intended to induce active immunity against H5N1 influenza through vaccine-elicited antiviral antibody and cellular immune responses. Panflu completed Phase II evaluation and received Chinese production licensure on April 2, 2008. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4634113/))

Brand names: Panflu
Other names: inactivated whole virion H5N1 vaccine, adjuvantedPan-flu

Targets

H5 HA (Influenza A hemagglutinin H5)

Beyond the preview

Go deeper on Panflu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panflu.

Explore the full profile